Tong B, Niu K, Ku W, Xie W, Dai Q, Hellström S, Duan M, et al.
Audiology & neuro-otology. Date of publication 2021 Jan 1;volume 26(1):11-16.
1. Audiol Neurootol. 2021;26(1):11-16. doi: 10.1159/000507911. Epub 2020 Jun 12.
Comparison of Therapeutic Results with/without Additional Hyperbaric Oxygen
Therapy in Idiopathic Sudden Sensorineural Hearing Loss: A Randomized
Prospective Study.
Tong B(1), Niu K(2)(3), Ku W(1)(4), Xie W(5), Dai Q(6), Hellström S(7), Duan
M(8)(9)(10)(11).
Author information:
(1)Department of Otolaryngology Head and Neck Surgery, The First Affiliated
Hospital of Anhui Medical University, Hefei, China.
(2)Department of Otolaryngology Head and Neck Surgery, The First Affiliated
Hospital of Jilin University, Jilin, China.
(3)Division of Ear, Nose and Throat Diseases, Department of Clinical Science,
Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
(4)Department of Otolaryngology Head and Neck Surgery, The People's Hospital of
Macheng City, Macheng, China.
(5)Department of Otolaryngology, Head and Neck Surgery, The Second Affiliated
Hospital of Nanchang University, Nanchang, China.
(6)Department of Otolaryngology, West China Hospital, Sichuan University,
Chengdu, China.
(7)Department of Otolaryngology Head and Neck, Karolinska Institutet, Stockholm,
Sweden.
(8)Department of Otolaryngology Head and Neck Surgery, The First Affiliated
Hospital of Anhui Medical University, Hefei, China, maoli.duan@ki.se.
(9)Department of Otolaryngology Head and Neck Surgery, The First Affiliated
Hospital of Jilin University, Jilin, China, maoli.duan@ki.se.
(10)Division of Ear, Nose and Throat Diseases, Department of Clinical Science,
Intervention and Technology, Karolinska Institutet, Stockholm, Sweden,
maoli.duan@ki.se.
(11)Department of Otolaryngology Head and Neck, Karolinska Institutet,
Stockholm, Sweden, maoli.duan@ki.se.
OBJECTIVE: To assess the efficacy of the combination of hyperbaric oxygen (HBO)
and pharmacological treatment in patients with idiopathic sudden sensorineural
hearing loss (ISSNHL) and define patients amenable for HBO therapy.
METHODS: Prospective, randomized, trial involving 136 cases with unilateral
ISSNHL that were randomly divided into 2 groups: the pharmacological treatment
(P) group and HBO + pharmacological treatment (HBO+P) group, which received
additional HBO for 14 days besides the pharmacological treatments. Pure tone
audiometry gain larger than 15 dBHL was defined as success, and the success rate
of each group was calculated.
RESULTS: The overall success rate of the HBO+P group and the P group is 60.6%
(40/66) and 42.9% (30/70), respectively (p < 0.05). Furthermore, patients with
mild-moderate baseline hearing loss, aged ≤50 years, receiving treatment in ≤14
days, or without accompanied dizziness/vertigo in the HBO+P group had higher
success rate than the P group (p < 0.05).
CONCLUSIONS: HBO combined with pharmacological treatments leads to better
hearing recovery than pharmacological treatments alone.
© 2020 S. Karger AG, Basel.
DOI: 10.1159/000507911
PMID: 32535600 [Indexed for MEDLINE]
